tirzepatide clinical trials near me New trial: Zepbound (tirzepatide) helped adults lose an average of 20.2% of their body weight—around 50 lbs—over 72 weeks, outperforming Wegovy's 13.7% (~33 lbs). Credit to: https://www.healthline.com/health-news/zepbound-wegovy-weight-loss New long COVID clinical trial

And with that, ready for another claim

doi: 10.1542/peds.113.3.565 233 HartleySLMacleanWEButlerMGZarconeJThompsonT

28 The combination of multiple medications and/or the financial burden may be too much for some patients

This observation aligns with a growing body of evidence suggesting that GLP-1 receptor agonists do far more than regulate blood sugar and appetite

Blood Sugar Fluctuations Because this medication encourages the pancreas to release insulin and prevents the liver from making too much glucose, your blood sugar levels become more stable

Racial and ethnic profiles were also comparable: approximately 45% of participants were White in both groups, and ~20% identified as Hispanic